Essa Pharma Stock Performance
| EPIX Stock | USD 6.25 0.15 2.34% |
The firm shows a Beta (market volatility) of 0.83, which means possible diversification benefits within a given portfolio. As returns on the market increase, ESSA Pharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding ESSA Pharma is expected to be smaller as well. ESSA Pharma has an expected return of -0.28%. Please make sure to confirm ESSA Pharma treynor ratio, accumulation distribution, as well as the relationship between the Accumulation Distribution and price action indicator , to decide if ESSA Pharma performance from the past will be repeated at future time.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days ESSA Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's forward indicators remain fairly strong which may send shares a bit higher in May 2024. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
Five Day Return (5.60) | Year To Date Return (0.78) | Ten Year Return (92.76) | All Time Return (92.76) |
Last Split Factor 1:20 | Dividend Date 2018-04-25 | Last Split Date 2018-04-25 |
1 | Exercise or conversion by Peter Virsik of 72782 shares of ESSA Pharma subject to Rule 16b-3 | 02/07/2024 |
2 | ESSA Pharma Inc Executive Peter Virsik Sells 72,782 Shares | 02/08/2024 |
3 | ESSA Pharma Inc Reports Q1 Fiscal 2024 Financial Results | 02/14/2024 |
4 | Disposition of 694 shares by Peter Virsik of ESSA Pharma at 8.98 subject to Rule 16b-3 | 03/05/2024 |
5 | ESSA Pharma Presents Updated Phase 1 Masofaniten Clinical Data at the 30th Annual Prostate Cancer ... - Barchart | 03/12/2024 |
6 | Acquisition by Cesano Alessandra of 200000 shares of ESSA Pharma at 9.04 subject to Rule 16b-3 | 03/25/2024 |
7 | ESSA Pharma Inc. Short Interest Down 5.2 percent in March - MarketBeat | 04/02/2024 |
8 | ESSA Pharma Is In A Strong Position To Grow Its Business | 04/08/2024 |
9 | ESSA Pharma to Present at the Jefferies London Healthcare Conference - The Globe and Mail | 04/11/2024 |
10 | Hedge funds investors in ESSA Pharma Inc. lost 12 percent last week but have reaped the benefits of longer-term growth | 04/16/2024 |
| Begin Period Cash Flow | 57.1 M |
ESSA |
ESSA Pharma Relative Risk vs. Return Landscape
If you would invest 779.00 in ESSA Pharma on January 26, 2024 and sell it today you would lose (154.00) from holding ESSA Pharma or give up 19.77% of portfolio value over 90 days. ESSA Pharma is currently does not generate positive expected returns and assumes 3.8766% risk (volatility on return distribution) over the 90 days horizon. In different words, 34% of stocks are less volatile than ESSA, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
ESSA Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for ESSA Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as ESSA Pharma, and traders can use it to determine the average amount a ESSA Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0724
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | EPIX |
Estimated Market Risk
| 3.88 actual daily | 34 66% of assets are more volatile |
Expected Return
| -0.28 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.07 actual daily | 0 Most of other assets perform better |
Based on monthly moving average ESSA Pharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of ESSA Pharma by adding ESSA Pharma to a well-diversified portfolio.
ESSA Pharma Fundamentals Growth
ESSA Stock prices reflect investors' perceptions of the future prospects and financial health of ESSA Pharma, and ESSA Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on ESSA Stock performance.
| Return On Equity | -0.17 | ||||
| Return On Asset | -0.13 | ||||
| Current Valuation | 141.38 M | ||||
| Shares Outstanding | 44.24 M | ||||
| Price To Earning | (1.12) X | ||||
| Price To Book | 2.48 X | ||||
| EBITDA | (26.46 M) | ||||
| Net Income | (26.58 M) | ||||
| Cash And Equivalents | 174.6 M | ||||
| Cash Per Share | 3.96 X | ||||
| Total Debt | 80.33 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 43.43 X | ||||
| Book Value Per Share | 3.19 X | ||||
| Cash Flow From Operations | (19.78 M) | ||||
| Earnings Per Share | (0.59) X | ||||
| Market Capitalization | 285.15 M | ||||
| Total Asset | 149.12 M | ||||
| Retained Earnings | (179.46 M) | ||||
| Working Capital | 145.3 M | ||||
| Current Asset | 10.02 M | ||||
| Current Liabilities | 3.63 M | ||||
About ESSA Pharma Performance
To evaluate ESSA Pharma Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when ESSA Pharma generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare ESSA Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand ESSA Pharma market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents ESSA's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 298.3 K | 313.3 K | |
| Return On Tangible Assets | (0.16) | (0.17) | |
| Return On Capital Employed | (0.16) | (0.17) | |
| Return On Assets | (0.16) | (0.17) | |
| Return On Equity | (0.21) | (0.20) |
Things to note about ESSA Pharma performance evaluation
Checking the ongoing alerts about ESSA Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for ESSA Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| ESSA Pharma generated a negative expected return over the last 90 days | |
| ESSA Pharma has high historical volatility and very poor performance | |
| Net Loss for the year was (26.58 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| ESSA Pharma currently holds about 174.6 M in cash with (19.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.96. | |
| ESSA Pharma has a very weak financial position based on the latest SEC disclosures | |
| Over 79.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from simplywall.st: Hedge funds investors in ESSA Pharma Inc. lost 12 percent last week but have reaped the benefits of longer-term growth |
- Analyzing ESSA Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether ESSA Pharma's stock is overvalued or undervalued compared to its peers.
- Examining ESSA Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating ESSA Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of ESSA Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of ESSA Pharma's stock. These opinions can provide insight into ESSA Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in ESSA Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy ESSA Stock please use our How to Invest in ESSA Pharma guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Complementary Tools for ESSA Stock analysis
When running ESSA Pharma's price analysis, check to measure ESSA Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ESSA Pharma is operating at the current time. Most of ESSA Pharma's value examination focuses on studying past and present price action to predict the probability of ESSA Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ESSA Pharma's price. Additionally, you may evaluate how the addition of ESSA Pharma to your portfolios can decrease your overall portfolio volatility.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |
Is ESSA Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ESSA Pharma. If investors know ESSA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ESSA Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.59) | Return On Assets (0.13) | Return On Equity (0.17) |
The market value of ESSA Pharma is measured differently than its book value, which is the value of ESSA that is recorded on the company's balance sheet. Investors also form their own opinion of ESSA Pharma's value that differs from its market value or its book value, called intrinsic value, which is ESSA Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ESSA Pharma's market value can be influenced by many factors that don't directly affect ESSA Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ESSA Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if ESSA Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ESSA Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.